Literature DB >> 17023084

Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.

Sandra Franco1, Cristina Tural, Bonaventura Clotet, Miguel Angel Martínez.   

Abstract

The hepatitis C virus (HCV) genotype 4 is spreading among southern European intravenous drug users, who are frequently co-infected with human immunodeficiency virus type 1 (HIV-1). Response to interferon (IFN) alpha-based therapies in HIV-1 positive patients co-infected with HCV genotype 4 is poor, similar to that obtained for HCV genotype 1 and much lower than for HCV genotypes 2 and 3. The lack of sequence data related to HCV of genotype 4 prompted us to sequence the complete genome of two genotype 4 variants isolated from two HIV-1 co-infected patients (24 and 25). Our aim was to investigate the evolutionary relationships of the former variants with other genotypes and/or genotype 4 subtypes. Sequence alignments and phylogenetic analysis from genomic regions 5'NC, core-E1 and NS5B revealed that the variants isolated from patients 24 and 25 (both subtyped 4c/4d by INNO-LIPA II HCV) belong to subtypes 4d and 4a, respectively. When looking at the complete genome sequence one of the variants showed a new genotype 4 subtype. Interestingly, sequence length differences in the interferon sensitivity determining region coding regions were observed when compared with sequences from other genotypes. Similarly, when the catalytic efficiency of the NS3/4 protease from patients 24 and 25 samples were determined, they displayed 70.6+/-7.7 and 23.5+/-3.4%, respectively, of the activity shown by genotype 1 NS3/4 proteases. Overall, pairwise comparison and phylogenetic analysis of nucleotide sequences of the complete genome or the different protein-encoding regions showed that genotype 4 sequences were more closely related to genotype 1 sequences. The description of new HCV genome variants may help our understanding of the HCV biology as well as the role of different genotypes in HCV treatment and therapy response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023084     DOI: 10.1016/j.virusres.2006.09.001

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  9 in total

1.  Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.

Authors:  Judith M Gottwein; Troels K H Scheel; Benoit Callendret; Yi-Ping Li; Heather B Eccleston; Ronald E Engle; Sugantha Govindarajan; William Satterfield; Robert H Purcell; Christopher M Walker; Jens Bukh
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

2.  Fitness landscape of human immunodeficiency virus type 1 protease quasispecies.

Authors:  Guerau Fernàndez; Bonaventura Clotet; Miguel Angel Martínez
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

3.  Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.

Authors:  Ester Aparicio; Sandra Franco; Mariona Parera; Cristina Andrés; Cristina Tural; Bonaventura Clotet; Miguel Angel Martínez
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

4.  Complete genomic sequences for hepatitis C virus subtypes 4b, 4c, 4d, 4g, 4k, 4l, 4m, 4n, 4o, 4p, 4q, 4r and 4t.

Authors:  Chunhua Li; Ling Lu; Xianghong Wu; Chuanxi Wang; Phil Bennett; Teng Lu; Donald Murphy
Journal:  J Gen Virol       Date:  2009-04-08       Impact factor: 3.891

5.  A set of reference sequences for the hepatitis C genotypes 4d, 4f, and 4k covering the full open reading frame.

Authors:  Thomas Kuntzen; Andrew Berical; Jean Ndjomou; Phil Bennett; Arne Schneidewind; Niall Lennon; Bruce W Birren; Carla Kuiken; Matthew R Henn; Peter Simmonds; Todd M Allen
Journal:  J Med Virol       Date:  2008-08       Impact factor: 2.327

6.  Virological surveillance, molecular phylogeny, and evolutionary dynamics of hepatitis C virus subtypes 1a and 4a isolates in patients from Saudi Arabia.

Authors:  Waleed H AlMalki; Imran Shahid; Ashraf N Abdalla; Ayman K Johargy; Muhammad Ahmed; Sajida Hassan
Journal:  Saudi J Biol Sci       Date:  2020-12-08       Impact factor: 4.219

7.  Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China.

Authors:  Yi Tan; Qi Hou Wei; Liu Jun Chen; Pui Chung Chan; Wen Sheng Lai; Ming Liang He; Hsiang Fu Kung; Shui Shan Lee
Journal:  PLoS One       Date:  2008-10-31       Impact factor: 3.240

8.  In vitro inhibition of hepatitis C virus by antisense oligonucleotides in PBMC compared to hepatoma cells.

Authors:  Samar Samir Youssef; Ahmed Mohamed Fahmy; Moataza Hassan Omran; Amr Saad Mohamed; Mohamed Ali El Desouki; Mostafa K El-Awady
Journal:  Biomed Res Int       Date:  2014-06-01       Impact factor: 3.411

9.  Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection.

Authors:  Dorota Zarębska-Michaluk; Jerzy Jaroszewicz; Anna Parfieniuk-Kowerda; Małgorzata Pawłowska; Ewa Janczewska; Hanna Berak; Justyna Janocha-Litwin; Jakub Klapaczyński; Krzysztof Tomasiewicz; Anna Piekarska; Rafał Krygier; Jolanta Citko; Olga Tronina; Krystyna Dobrowolska; Robert Flisiak
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.